A Five-LLPS Gene Risk Score Prognostic Signature Predicts Survival in Hepatocellular Carcinoma.
Journal
International journal of genomics
ISSN: 2314-4378
Titre abrégé: Int J Genomics
Pays: United States
ID NLM: 101605206
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
10
2022
revised:
17
01
2023
accepted:
31
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Primary liver cancer, dominated by hepatocellular carcinoma (HCC), is one of the most common cancer types and the third leading cause of cancer death in 2020. Previous studies have shown that liquid-liquid phase separation (LLPS) plays an important role in the occurrence and development of cancer including HCC, but its influence on the patient prognosis is still unknown. It is necessary to explore the effect of LLPS genes on prognosis to accurately forecast the prognosis of HCC patients and identify relevant targeted therapeutic sites. Using The Cancer Genome Atlas dataset and PhaSepDB dataset, we identified LLPS genes linked to the overall survival (OS) of HCC patients. We applied Least Absolute Shrinkage and Selection Operator (LASSO) Cox penalized regression analysis to choose the best genes for the risk score prognostic signature. We then analysed the validation dataset and evaluated the effectiveness of the risk score prognostic signature. Finally, we performed quantitative real-time PCR experiments to validate the genes in the prognostic signature. We identified 43 differentially expressed LLPS genes that were associated with the OS of HCC patients. Five of these genes ( Our study constructed a five-LLPS gene risk score signature that can be applied as an effective and convenient prognostic tool. These five genes might serve as potential targets for therapy and the treatment of HCC.
Sections du résumé
Background
UNASSIGNED
Primary liver cancer, dominated by hepatocellular carcinoma (HCC), is one of the most common cancer types and the third leading cause of cancer death in 2020. Previous studies have shown that liquid-liquid phase separation (LLPS) plays an important role in the occurrence and development of cancer including HCC, but its influence on the patient prognosis is still unknown. It is necessary to explore the effect of LLPS genes on prognosis to accurately forecast the prognosis of HCC patients and identify relevant targeted therapeutic sites.
Methods
UNASSIGNED
Using The Cancer Genome Atlas dataset and PhaSepDB dataset, we identified LLPS genes linked to the overall survival (OS) of HCC patients. We applied Least Absolute Shrinkage and Selection Operator (LASSO) Cox penalized regression analysis to choose the best genes for the risk score prognostic signature. We then analysed the validation dataset and evaluated the effectiveness of the risk score prognostic signature. Finally, we performed quantitative real-time PCR experiments to validate the genes in the prognostic signature.
Results
UNASSIGNED
We identified 43 differentially expressed LLPS genes that were associated with the OS of HCC patients. Five of these genes (
Conclusion
UNASSIGNED
Our study constructed a five-LLPS gene risk score signature that can be applied as an effective and convenient prognostic tool. These five genes might serve as potential targets for therapy and the treatment of HCC.
Identifiants
pubmed: 36873244
doi: 10.1155/2023/7299276
pmc: PMC9977538
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7299276Informations de copyright
Copyright © 2023 Wenwen Lai et al.
Déclaration de conflit d'intérêts
The author(s) declare(s) that they have no conflicts of interest.
Références
Cancer Sci. 2020 Sep;111(9):3155-3163
pubmed: 32594560
Int J Mol Sci. 2020 Apr 26;21(9):
pubmed: 32357520
Science. 2009 Jun 26;324(5935):1729-32
pubmed: 19460965
Med Oncol. 2015 Apr;32(4):96
pubmed: 25731616
Breast Cancer. 2020 May;27(3):363-371
pubmed: 31728872
Oncology. 2007;72(5-6):410-6
pubmed: 18196928
Science. 2020 Jun 19;368(6497):1386-1392
pubmed: 32554597
Onco Targets Ther. 2018 Mar 12;11:1333-1343
pubmed: 29559792
EMBO J. 2019 Aug 15;38(16):e101379
pubmed: 31267591
Int J Epidemiol. 2007 Oct;36(5):1001-8
pubmed: 17496055
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Cancer Res. 2018 Sep 15;78(18):5203-5215
pubmed: 30012673
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Cancer Cell. 2021 Feb 8;39(2):174-192
pubmed: 33417833
Cancer. 2010 Apr 1;116(7):1629-37
pubmed: 20151426
Nat Rev Mol Cell Biol. 2017 May;18(5):285-298
pubmed: 28225081
Med Oncol. 2014 Aug;31(8):131
pubmed: 25031071
Cell. 2020 Sep 17;182(6):1531-1544.e15
pubmed: 32846158
Nat Commun. 2016 Oct 05;7:12992
pubmed: 27703150
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Surg Oncol. 2018 Jun;117(8):1833-1840
pubmed: 29761507
Cancer Cell Int. 2018 Dec 17;18:208
pubmed: 30564064
Acta Biochim Biophys Sin (Shanghai). 2019 Mar 1;51(3):285-292
pubmed: 30883648
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cancer Metastasis Rev. 2016 Jun;35(2):179-99
pubmed: 27067725
Science. 2019 Mar 8;363(6431):1098-1103
pubmed: 30846600
Adv Sci (Weinh). 2022 Mar;9(8):e2103817
pubmed: 35072355
Pharmacol Res. 2015 Oct;100:250-4
pubmed: 26305432
Cell. 2019 Jan 24;176(3):419-434
pubmed: 30682370
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
J Neuropathol Exp Neurol. 2019 Sep 1;78(9):865-870
pubmed: 31369092
Annu Rev Microbiol. 2018 Sep 08;72:255-271
pubmed: 30200855
Am J Transl Res. 2019 Nov 15;11(11):6924-6937
pubmed: 31814897
Aging (Albany NY). 2020 Nov 20;12(23):23849-23871
pubmed: 33221766
Stat Med. 2014 Jun 30;33(14):2379-89
pubmed: 24399671
Urol Oncol. 2012 Nov-Dec;30(6):893-9
pubmed: 21396842
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Clin Transl Hepatol. 2018 Mar 28;6(1):69-78
pubmed: 29607307
Curr Biol. 2018 Apr 23;28(8):R381-R385
pubmed: 29689219
Nat Cell Biol. 2020 Feb;22(2):151-158
pubmed: 32015439
Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):52-53
pubmed: 29963462
Annu Rev Genet. 2019 Dec 3;53:171-194
pubmed: 31430179
Annu Rev Biophys. 2020 May 6;49:107-133
pubmed: 32004090